| Popis: |
The treatment of eating disorders should include the utilization of nonpharmacologic therapy and, when appropriate, pharmacotherapy to address symptoms of the eating disorder and any psychiatric comorbidities present. Due to the complex nature of eating disorders, a multi-disciplinary team approach to care is an essential component for maximizing treatment outcomes. Currently there are no FDA approved medications for anorexia nervosa; however, SSRI antidepressants may help with comorbid symptoms. The SSRI, fluoxetine, is FDA approved for use in bulimia nervosa for symptoms associated with bulimia, also addressing psychiatric comorbidities. Lisdexamfetamine is an FDA approved treatment for use in binge-eating disorder, helping to reduce binge episodes. Other pharmacotherapeutic options have demonstrated efficacy benefits in eating disorders, such as topiramate treatment in bulimia and binge eating disorder; however, nonpharmacologic therapy remains an essential first-line treatment across eating disorders and should always be employed regardless of whether or not pharmacotherapy is also part of the treatment plan. This review contains 3 tables, 4 figures, and 30 references. Keywords : Anorexia, bulimia, binge-eating disorder, pharmacotherapy, treatment, psychopharmacology, serotonin, olanzapine, eating disorders |
